In studies specific to primary liver cancer, such as CheckMate040 and CheckMate459, patients with PD-L1 expression ≥1% and PD-L1 expression<1% exhibited significant differences in median overall survival time (OS) and objective response rates (ORR) (55, 56). This evidence concerns the gene CD274 and liver cancer.